MTNB - Matinas Biopharma Holdings Inc
Previous close
0.0933
0 0%
Share volume: 2,782,075
Last Updated: Tue 27 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.09
0.00
0.00%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
| Report Date | 2022-05-12 | 2022-08-11 | 2022-11-02 | 2023-03-15 | 2023-05-10 | 2023-08-09 | 2023-11-08 | 2024-03-27 | |
| Assets | |||||||||
| Total Assets | 55.785 M | 52.416 M | 47.546 M | 44.819 M | 38.262 M | 34.025 M | 29.791 M | 25.104 M | |
| Current Assets | 45.119 M | 41.924 M | 37.099 M | 34.532 M | 28.206 M | 24.000 M | 19.989 M | 15.543 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.199 M | 3.372 M | 3.998 M | 5.719 M | 3.299 M | 1.437 M | 1.723 M | 1.737 M | |
| Short Term Investments | 1.199 M | 3.372 M | 3.998 M | 5.719 M | 3.299 M | 1.437 M | 1.723 M | 1.737 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 43.870 M | 38.503 M | 33.051 M | 28.763 M | 24.857 M | 22.513 M | 18.216 M | 13.756 M | |
| Total Non-current Assets | 10.666 M | 10.491 M | 10.447 M | 10.287 M | 10.056 M | 10.025 M | 9.802 M | 9.561 M | |
| Property Plant Equipment | 2.013 M | 1.983 M | 2.144 M | 2.091 M | 1.998 M | 2.103 M | 2.021 M | 1.923 M | |
| Other Assets | 4.099 M | 3.955 M | 3.749 M | 3.643 M | 3.505 M | 3.369 M | 3.228 M | 3.085 M | |
| Intangible Assets | 3.017 M | 3.017 M | 3.017 M | 3.017 M | 3.017 M | 3.017 M | 3.017 M | 3.017 M | |
| Goodwill | 1.336 M | 1.336 M | 1.336 M | 1.336 M | 1.336 M | 1.336 M | 1.336 M | 1.336 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 55.785 M | 52.416 M | 47.546 M | 44.819 M | 38.262 M | 34.025 M | 29.791 M | 25.104 M | |
| Total liabilities | 8.103 M | 9.567 M | 8.927 M | 8.182 M | 5.637 M | 6.171 M | 6.641 M | 5.858 M | |
| Total current liabilities | 3.768 M | 5.382 M | 4.902 M | 4.286 M | 1.896 M | 2.589 M | 3.229 M | 2.622 M | |
| Accounts Payable | 1.352 M | 497.151 K | 656.717 K | 618.000 K | 516.000 K | 604.000 K | 835.000 K | 514.000 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 575.836 K | 590.768 K | 547.936 K | 569.000 K | 589.000 K | 613.000 K | 637.000 K | 661.000 K | |
| Long term debt | 3.993 M | 3.844 M | 3.684 M | 3.555 M | 3.400 M | 3.241 M | 3.071 M | 2.895 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 47.682 M | 42.849 M | 38.619 M | 36.637 M | 32.625 M | 27.854 M | 23.150 M | 19.246 M | |
| Common stock | 216.645 M | 216.865 M | 216.865 M | 216.872 M | 217.265 M | 217.265 M | 217.265 M | 217.265 M | |
| Retained earnings | -137.612 M | -143.535 M | -148.997 M | -152.631 M | -158.144 M | -164.204 M | -170.259 M | -175.573 M |